OBJECTIVES: The objective of this study is to descriptively evaluate the characteristics of patients receiving disease modifying therapies (DMTs) for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the US.  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed DMTs between January 2010 to December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan for a year. Descriptive statistics and chi-square tests were performed on the data. RESULTS: There were 741,065 patients that met the study criteria. And, all of these patients were on any of one of the following DMTs: Gilenya (N=28509 (3.8%)), Extavia (N=3461 (0.5%)), Tysabri (N=7915 (1.1%)), Rebif (N=141373 (19.1%)), Copaxone (N=291871 (39.4%)), Avonex (N=185273 (25%)), Betaseron (N=82147 (11.1%)) and Aubagio (N=157). The mean age of the patients was 52.38 ± 10.50 years, 75.7% of the patients were females, and majority of the patients were between 41 to 64 years of age (73.5%). Thirty two percent of the patients were from East, 34.6% were from Midwest, 25% from South and 7.8% is from West region. 56.6% of the patients were on a group coverage plan and 62.6% of the patients were on a DMT prescription that is under their health plan formulary.  Majority of the patients were prescribed DMTs for 30 days (92.9%) with a significant difference between the drugs (P<0.001). Most of the patients were enrolled in the same health plan for 5.36 ± 2.40 years. CONCLUSIONS: Around 40% of the patients were on generic Copaxone for the treatment of RRMS. The majority of the patients were females, ages between 41 to 64 years, enrolled in the same health plan for 5 years and received prescription supply for 30 days or less.